HomeAboutRankingsData Sources
ยฉ 2026 GeneE
๐Ÿงฌ
GeneE
26 sources retrieved ยท Most recent: April 2026 ยท Index updated 14 days ago
โ“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TUBA4A
tubulin alpha 4a
Chromosome 2 ยท 2q35
NCBI Gene: 7277Ensembl: ENSG00000127824.16HGNC: HGNC:12407UniProt: P68366
273PubMed Papers
24Diseases
86Drugs
18Pathogenic Variants
RESEARCH IMPACT
Trending
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
โœ“ Experimental GO Evidenceโœ“ Swiss-Prot Reviewed
microtubule cytoskeletonprotein kinase bindingprotein bindingmicrotubuleamyotrophic lateral sclerosisnon-small cell lung carcinomabreast cancerbreast neoplasm
โœฆAI Summary

TUBA4A encodes alpha-tubulin 4A, a major constituent of microtubules that form the cytoskeletal framework essential for cell structure and function 1. As a core component of microtubule heterodimers, TUBA4A contributes to GTP-dependent microtubule polymerization and stabilization, with GTPase activity regulating tubulin-GTP hydrolysis 1. Beyond structural roles, TUBA4A interacts with regulatory proteins; notably, acetylated TUBA4A sequesters the cardiac transcription factor YAP in the cytoplasm, inhibiting heart regeneration after myocardial infarction 2. Pathogenic TUBA4A variants disrupt microtubule organization and dynamics, causing diverse neuromuscular and developmental phenotypes 13. Originally associated with amyotrophic lateral sclerosis and frontotemporal dementia through impaired cytoskeletal integrity 4, TUBA4A variants now encompass a broader spectrum including hereditary spastic ataxia, congenital myopathy, and axial myopathies with variable onset from infancy to adulthood 13. Biallelic variants cause oocyte meiotic arrest and recurrent preimplantation embryo developmental arrest through spindle defects 5. Muscle pathology reveals protein accumulation with autophagic features, indicating broader proteostasis dysfunction 3. These findings establish TUBA4A-related disorders as myo-tubulinopathies with multisystem manifestations, underscoring TUBA4A's critical roles in neurodegeneration, myogenesis, and reproductive development.

Sources cited
1
TUBA4A identified as novel ALS-associated gene; variants impair cytoskeletal integrity
PMID: 29154141
2
TUBA4A missense variants cause ataxia and spasticity with altered microtubule organization
PMID: 38884572
3
TUBA4A variants cause myo-tubulinopathies with primary myopathy and multisystem proteinopathy
PMID: 41678358
4
Acetylated TUBA4A sequesters YAP in cytoplasm and inhibits cardiac regeneration
PMID: 39185559
5
Biallelic TUBA4A variants cause oocyte arrest and preimplantation embryo developmental arrest through spindle defects
PMID: 39209701
Disease Associationsโ“˜24
amyotrophic lateral sclerosisOpen Targets
0.78Strong
non-small cell lung carcinomaOpen Targets
0.61Moderate
breast cancerOpen Targets
0.61Moderate
breast neoplasmOpen Targets
0.60Moderate
neoplasmOpen Targets
0.60Moderate
breast carcinomaOpen Targets
0.60Moderate
amyotrophic lateral sclerosis type 22Open Targets
0.60Moderate
goutOpen Targets
0.59Moderate
Hodgkins lymphomaOpen Targets
0.58Moderate
multiple myelomaOpen Targets
0.58Moderate
familial Mediterranean feverOpen Targets
0.58Moderate
cervical cancerOpen Targets
0.58Moderate
prostate cancerOpen Targets
0.58Moderate
diffuse large B-cell lymphomaOpen Targets
0.58Moderate
head and neck malignant neoplasiaOpen Targets
0.57Moderate
lymphomaOpen Targets
0.57Moderate
stomach neoplasmOpen Targets
0.57Moderate
prostate neoplasmOpen Targets
0.56Moderate
adenocarcinomaOpen Targets
0.56Moderate
head and neck neoplasiaOpen Targets
0.56Moderate
Congenital myopathy 26UniProt
Frontotemporal dementia and/or amyotrophic lateral sclerosis 9UniProt
Oocyte/zygote/embryo maturation arrest 23UniProt
Spastic ataxia 11, autosomal dominantUniProt
Pathogenic Variants18
NM_006000.3(TUBA4A):c.1147G>A (p.Ala383Thr)Likely pathogenic
Amyotrophic lateral sclerosis type 22
โ˜…โ˜†โ˜†โ˜†2024โ†’ Residue 383
NM_006000.3(TUBA4A):c.995_997delinsA (p.Ile332fs)Likely pathogenic
not provided
โ˜…โ˜†โ˜†โ˜†2024โ†’ Residue 332
NM_006000.3(TUBA4A):c.958C>T (p.Arg320Cys)Likely pathogenic
Amyotrophic lateral sclerosis type 22|not provided
โ˜…โ˜†โ˜†โ˜†2023โ†’ Residue 320
NM_006000.3(TUBA4A):c.1051_1055dup (p.Lys352fs)Likely pathogenic
not provided
โ˜…โ˜†โ˜†โ˜†2021โ†’ Residue 352
NM_006000.3(TUBA4A):c.225del (p.Ile75fs)Likely pathogenic
not provided
โ˜…โ˜†โ˜†โ˜†2020โ†’ Residue 75
NM_006000.3(TUBA4A):c.761_762del (p.Glu254fs)Likely pathogenic
not provided
โ˜…โ˜†โ˜†โ˜†2019โ†’ Residue 254
NM_006000.3(TUBA4A):c.907G>C (p.Val303Leu)Pathogenic
Oocyte/zygote/embryo maturation arrest 23
โ˜†โ˜†โ˜†โ˜†2025โ†’ Residue 303
NM_006000.3(TUBA4A):c.850G>A (p.Glu284Lys)Pathogenic
Oocyte/zygote/embryo maturation arrest 23
โ˜†โ˜†โ˜†โ˜†2025โ†’ Residue 284
NM_006000.3(TUBA4A):c.857T>C (p.Leu286Pro)Pathogenic
Oocyte/zygote/embryo maturation arrest 23
โ˜†โ˜†โ˜†โ˜†2025โ†’ Residue 286
NM_006000.3(TUBA4A):c.190del (p.Arg64fs)Pathogenic
Amyotrophic lateral sclerosis type 22
โ˜†โ˜†โ˜†โ˜†2025โ†’ Residue 64
NM_006000.3(TUBA4A):c.517C>T (p.Pro173Ser)Pathogenic
Spastic ataxia 11, autosomal dominant
โ˜†โ˜†โ˜†โ˜†2025โ†’ Residue 173
NM_006000.3(TUBA4A):c.518C>G (p.Pro173Arg)Pathogenic
Spastic ataxia 11, autosomal dominant
โ˜†โ˜†โ˜†โ˜†2025โ†’ Residue 173
NM_006000.3(TUBA4A):c.229G>A (p.Glu77Lys)Pathogenic
Oocyte/zygote/embryo maturation arrest 23
โ˜†โ˜†โ˜†โ˜†2025โ†’ Residue 77
NM_006000.3(TUBA4A):c.1040G>A (p.Cys347Tyr)Pathogenic
Oocyte/zygote/embryo maturation arrest 23
โ˜†โ˜†โ˜†โ˜†2025โ†’ Residue 347
NM_006000.3(TUBA4A):c.685C>T (p.Arg229Cys)Pathogenic
Oocyte/zygote/embryo maturation arrest 23
โ˜†โ˜†โ˜†โ˜†2025โ†’ Residue 229
NM_006000.3(TUBA4A):c.1220G>A (p.Trp407Ter)Pathogenic
Amyotrophic lateral sclerosis type 22
โ˜†โ˜†โ˜†โ˜†2014โ†’ Residue 407
NM_006000.3(TUBA4A):c.433A>C (p.Thr145Pro)Pathogenic
Amyotrophic lateral sclerosis type 22
โ˜†โ˜†โ˜†โ˜†2014โ†’ Residue 145
NM_006000.3(TUBA4A):c.959G>A (p.Arg320His)Pathogenic
Amyotrophic lateral sclerosis type 22
โ˜†โ˜†โ˜†โ˜†2014โ†’ Residue 320
View on ClinVar โ†—
Drug Targets86
AGS-16C3FPhase II
Tubulin disrupting agent
renal cell carcinoma
ANETUMAB RAVTANSINEPhase II
Tubulin inhibitor
malignant pleural mesothelioma
ANG1005Phase II
Tubulin inhibitor
ANVATABART OPADOTINPhase II/III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
APRUTUMAB IXADOTINPhase I
Fibroblast growth factor receptor 2 binding agent
cancer
ASG-5MEPhase I
Choline transporter-like protein 4 binding agent
Malignant Pancreatic Neoplasm
AVE-9633Phase I
Myeloid cell surface antigen CD33 binding agent
myeloid leukemia
AZINTUXIZUMAB VEDOTINPhase I
SLAM family member 7 binding agent
multiple myeloma
BELANTAMAB MAFODOTINApproved
Tumor necrosis factor receptor superfamily member 17 binding agent
multiple myeloma
BIIB-015Phase I
Teratocarcinoma-derived growth factor 1 binding agent
BIVATUZUMAB MERTANSINEUNKNOWN
Tubulin inhibitor
BMS-275183Phase II
Tubulin stabiliser
BRENTUXIMAB VEDOTINApproved
Tubulin inhibitor
CABAZITAXELApproved
Tubulin inhibitor
prostate cancer
CANTUZUMAB MERTANSINEPhase II
Tubulin inhibitor
non-small cell lung carcinoma
CANTUZUMAB RAVTANSINEPhase II
Mucin-1 binding agent
stomach neoplasm
COLCHICINEApproved
Tubulin inhibitor
familial Mediterranean fever
COLTUXIMAB RAVTANSINEPhase II
Tubulin inhibitor
diffuse large B-cell lymphoma
CROLIBULINPhase I/II
Tubulin inhibitor
DAVUNETIDEPhase III
Tubulin stabiliser
Cognitive impairment
DENINTUZUMAB MAFODOTINPhase II
B-lymphocyte antigen CD19 binding agent
diffuse large B-cell lymphoma
DEPATUXIZUMAB MAFODOTINPhase III
Epidermal growth factor receptor erbB1 binding agent
glioblastoma multiforme
DISITAMAB VEDOTINPhase III
Receptor tyrosine-protein kinase erbB-2 binding agent
breast cancer
DOCETAXELApproved
Tubulin inhibitor
DOCETAXEL ANHYDROUSApproved
Tubulin stabiliser
prostate cancer
DOLASTATIN-10Phase II
Tubulin inhibitor
ENAPOTAMAB VEDOTINPhase I/II
Tyrosine-protein kinase receptor UFO binding agent
ENFORTUMAB VEDOTINApproved
Nectin-4 binding agent
EPOTHILONE DPhase II
Tubulin stabiliser
breast cancer
ERIBULINApproved
Tubulin inhibitor
breast cancer
ERIBULIN MESYLATEApproved
Tubulin inhibitor
breast cancer
FOSBRETABULINPhase III
Tubulin disrupting agent
thyroid cancer
FOSBRETABULIN DISODIUMPhase II
Tubulin inhibitor
neuroendocrine carcinoma
FOSBRETABULIN TROMETHAMINEPhase II/III
Tubulin disrupting agent
ovarian cancer
GLEMBATUMUMAB VEDOTINApproved
Transmembrane glycoprotein NMB binding agent
lymphoma
IMGN-388Phase I
Vitronectin receptor alpha binding agent
INDATUXIMAB RAVTANSINEPhase II
Syndecan-1 binding agent
multiple myeloma
INDIBULINPhase II
Tubulin inhibitor
INDUSATUMAB VEDOTINPhase II
Heat-stable enterotoxin receptor binding agent
IXABEPILONEApproved
Tubulin inhibitor
breast cancer
KOS-1584Phase II
Tubulin stabiliser
non-small cell lung carcinoma
LADIRATUZUMAB VEDOTINPhase II
Zinc transporter ZIP6 binding agent
breast cancer
LAROTAXELPhase III
Tubulin stabiliser
urinary bladder carcinoma
LEXIBULINPhase II
Tubulin inhibitor
glioblastoma multiforme
LIFASTUZUMAB VEDOTINPhase II
Sodium-dependent phosphate transport protein 2B binding agent
ovarian cancer
LORVOTUZUMAB MERTANSINEPhase II
Neural cell adhesion molecule 1 binding agent
MECBOTAMAB VEDOTINPhase II
Tyrosine-protein kinase receptor UFO binding agent
ovarian cancer
MILATAXELPhase II
Tubulin inhibitor
MIRVETUXIMAB SORAVTANSINEApproved
Folate receptor alpha binding agent
ovarian cancer
MLN-2704Phase I/II
Glutamate carboxypeptidase II binding agent
prostate cancer
OMBRABULINPhase III
Tubulin inhibitor
sarcoma
PACLITAXELApproved
Tubulin inhibitor
PACLITAXEL DOCOSAHEXAENOIC ACIDPhase III
Tubulin stabiliser
non-small cell lung carcinoma
PACLITAXEL POLIGLUMEXApproved
Tubulin stabiliser
neoplasm
PATUPILONEPhase III
Tubulin stabiliser
PF-06263507Phase I
Tubulin inhibitor
PINATUZUMAB VEDOTINPhase II
CD22 binding agent
diffuse large B-cell lymphoma
PLINABULINPhase III
Tubulin inhibitor
non-small cell lung carcinoma
PLOCABULINPhase II
Tubulin inhibitor
colorectal cancer
POLATUZUMAB VEDOTINApproved
Tubulin inhibitor
diffuse large B-cell lymphoma
PRALUZATAMAB RAVTANSINEPhase II
Tubulin inhibitor
neoplasm
RG-7598Phase I
Fc receptor-like protein 5 binding agent
multiple myeloma
RG-7600Phase I
Tubulin inhibitor
ovarian cancer
RG-7636Phase I
Tubulin inhibitor
melanoma
RG-7841Phase I
Lymphocyte antigen 6E binding agent
SAGOPILONEPhase II
Tubulin stabiliser
breast cancer
SAR-566658Phase II
Tubulin inhibitor
triple-negative breast cancer
SOBLIDOTINPhase II
Tubulin inhibitor
SOFITUZUMAB VEDOTINPhase I
Mucin-16 binding agent
fallopian tube cancer
T-900607Phase II
Tubulin disrupting agent
hepatocellular carcinoma
TELISOTUZUMAB VEDOTINPhase III
Hepatocyte growth factor receptor binding agent
non-small cell lung carcinoma
TISOTUMAB VEDOTINApproved
Coagulation factor III binding agent
cervical cancer
TRASTUZUMAB BOTIDOTINPhase III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
TRASTUZUMAB EMTANSINEApproved
Receptor protein-tyrosine kinase erbB-2 binding agent
TUSAMITAMAB RAVTANSINEPhase III
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
non-small cell lung carcinoma
VANDORTUZUMAB VEDOTINPhase I
Metalloreductase STEAP1 binding agent
prostate cancer
VERUBULINPhase II
Tubulin disrupting agent
VINBLASTINEApproved
Tubulin inhibitor
VINBLASTINE SULFATEApproved
Tubulin inhibitor
lymphoma
VINCRISTINEApproved
Tubulin inhibitor
VINCRISTINE SULFATEApproved
Tubulin inhibitor
VINFLUNINEApproved
Tubulin inhibitor
VINFLUNINE DITARTRATEApproved
Tubulin inhibitor
benign urinary system neoplasm
VINORELBINEApproved
Tubulin inhibitor
VINORELBINE TARTRATEApproved
Tubulin inhibitor
VORSETUZUMAB MAFODOTINPhase I
Tubulin inhibitor
renal cell carcinoma
Related Genes
ACTBProtein interaction100%TUBBProtein interaction99%DYNC1I1Protein interaction96%GJA1Protein interaction96%MAPTProtein interaction96%TBCAProtein interaction96%
Tissue Expression6 tissues
Brain
100%
Heart
67%
Bone Marrow
61%
Lung
44%
Liver
27%
Ovary
11%
Gene Interaction Network
Click a node to explore
TUBA4AACTBTUBBDYNC1I1GJA1MAPTTBCA
PROTEIN STRUCTURE
Preparing viewerโ€ฆ
AlphaFoldAI-predicted ยท UniProt P68366
View on AlphaFold โ†—
Constraintโ“˜
LOEUFโ“˜
0.94LoF Tolerant
pLIโ“˜
0.00Tolerant
Observed/Expected LoF0.67 [0.48โ€“0.94]
RankingsWhere TUBA4A stands among ~20K protein-coding genes
  • #1,346of 20,598
    Most Researched273 ยท top 10%
  • #61of 1,025
    FDA-Approved Drug Targets25 ยท top 10%
  • #2,267of 5,498
    Most Pathogenic Variants18
  • #8,810of 17,882
    Most Constrained (LOEUF)0.94
Genes detectedTUBA4A
Sources retrieved26 papers
Response timeโ€”
๐Ÿ“„ Sources
26โ–ผ
1
Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications.
PMID: 29154141
Lancet Neurol ยท 2018
1.00
2
Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.
PMID: 35302338
Eur J Transl Myol ยท 2022
0.90
3
De novo and inherited monoallelic variants in TUBA4A cause ataxia and spasticity.
PMID: 38884572
Brain ยท 2024
0.80
4
TUBA4A may not be a significant genetic factor in Chinese ALS patients.
PMID: 26465396
Amyotroph Lateral Scler Frontotemporal Degener ยท 2015
0.72
5
Missense variants in
PMID: 40666348
medRxiv ยท 2025
0.70